CReDO Science develops optimized, whole-plant botanical drug formulas for specific indications and provides clinical consulting through at least Phase II — for companies pursuing the FDA Botanical Drug pathway with the expertise, discipline, and staying power it demands. It is a long road. We have walked it. And we know how to get there.
We develop the botanical drug formula from the ground up — whole-plant, indication-specific, and optimized for the condition being treated. Our intellectual property, your license — structured with the guardrails that protect both the science and your program. This is not a generic formula dressed up for your indication. It is a complex, scientifically grounded formulation built from the endocannabinoid system out, drawing on decades of original research and clinical trial experience.
Once the formula is licensed, we stay. CReDO provides ongoing clinical consulting through at least Phase II — trial design, dosing strategy, regulatory navigation, and the kind of real-time scientific guidance that only comes from a team that has been inside more than 20 Phase I–III cannabis clinical trials. We have sat in those rooms. We know what the FDA expects, what trial designs hold up, and where programs fail.
Together, these two components give your program the scientific foundation and the clinical continuity that botanical drug development requires.
The FDA's Botanical Drug Development guidance provides a distinct regulatory route for whole-plant cannabis-based medicines — one that recognizes the complexity of botanical drugs and creates a pathway appropriate to them. It is not a shortcut. It is a rigorous, well-defined process that rewards scientific discipline and sound formulation from the start.
CReDO knows this pathway. We have built programs around it, and we bring that experience to every engagement.
The federal regulatory environment for cannabis-based medicines is shifting — and for companies serious about drug development, this is the right moment to move.
In December 2025, President Trump signed an executive order directing the expedited rescheduling of marijuana from Schedule I to Schedule III of the Controlled Substances Act. The Department of Justice has already placed FDA-approved cannabis products and state-licensed medical cannabis preparations under Schedule III, with a broader administrative hearing underway. The practical effect for drug development: reduced research barriers, eased licensing requirements for researchers, and a clear federal signal that the medical use of cannabis has scientific legitimacy.
Rescheduling does not change the FDA's standards for safety and efficacy — which means the rigorous, science-first approach CReDO has always taken is not just the right approach. It is now the only approach that positions a program for long-term success in a more active regulatory environment.
Companies that have been watching and waiting now have reason to move. CReDO is ready.
CReDO has developed and licensed botanical drug formulas currently in active clinical research on two indications:
• A whole-plant formula addressing ALS symptoms, licensed to an international partner and advancing toward clinical trials in 2027 on the FDA Botanical Drug pathway across multiple countries.
• A whole-plant formula for menopause symptom relief, licensed to an international partner and currently in US-based clinical trials.
In both cases, CReDO formulated the drug, negotiated the license, and has remained engaged as clinical consulting partner through the trial process. This is the model. This is what we do.
If you are an investor interested in learning more about either active program, we invite you to reach out directly.
CReDO assembles the right expertise for each project.
Our extended network includes veteran basic science researchers, clinicians, and regulatory specialists — including alums of GW Pharmaceuticals, the company that brought Sativex® and Epidiolex® to market through the FDA process. They are brought in on a project basis, contributing targeted expertise precisely when and where it's needed, without the overhead of a large standing organization.
This is how elite scientific consultancies work. The result is a lean, senior team — no junior staff learning on your program.
CReDO works with a small number of partners each year. The right fit looks like this:
You are pursuing the FDA Botanical Drug Development pathway — committed to doing this properly. You have the fundraising capacity to see drug development through and understand this is a long-term investment. You are open to guidance on formulation, because the science drives the formula, not the other way around. And you have an indication in mind that is either underserved, complex, or both.
We have a particular affinity for orphan indications and formulation challenges that others consider too complicated. That complexity is where our expertise is most valuable.
We don't validate existing formulas. If you have a product already built and are looking for scientific credibility to attach to it, we are not the right partner. CReDO builds the formula or we're not involved in formulation — because that is how we protect the integrity of every program we're associated with, and ultimately how we protect you.
We also don't work with clients who aren't open to taking guidance. Our value is the science. If the science can't drive the decisions, we can't do our best work.
Department of Medicine, University of British Columbia; Medical Director, Greenleaf Medical Clinic
We work with a small number of partners each year. If your program is a potential fit, we'd like to hear about it.
